Linda C. Griffin
Stanford University
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Linda C. Griffin.
The Annals of Thoracic Surgery | 1994
Abe DeAnda; Steven Coutre; Marc R. Moon; Conrad M. Vial; Linda C. Griffin; Veronica S. Law; Masashi Komeda; Lawrence L. K. Leung; D. Craig Miller
Heparin is normally used for anticoagulation during cardiopulmonary bypass (CPB), but its use is contraindicated in patients with a history of heparin-induced thrombocytopenia, heparin-provoked thrombosis, or both. Heparin therapy can also be ineffective due to heparin resistance. A short-acting, oligonucleotide-based thrombin inhibitor (thrombin aptamer) may potentially serve as a substitute for heparin in these and other clinical situations. We tested a novel thrombin aptamer in a canine CPB pilot study to determine its anticoagulant efficacy, the resultant changes in coagulation variables, and the aptamers clearance mechanisms and pharmacokinetics. Seven dogs were studied initially: Four received varied doses of the aptamer (to establish the pharmacokinetic profile) and 3 received heparin. Subsequently, 4 other dogs underwent CPB, receiving a constant infusion of the aptamer before CPB (to characterize the baseline coagulation status), with partial CPB and hemodilution, during 60 minutes of total CPB, and, finally, after a 2-hour recovery period. At a 0.5 mg.kg-1.min-1 dose, the activated clotting time rose with aptamer infusion from 106 +/- 12 seconds to 187 +/- 8 seconds (+/- 1 standard deviation) (p = 0.014), increased further with hemodilution (to 259 +/- 41 seconds; p = 0.017), and was even more prolonged during total CPB (> 1,500 seconds; p < 0.001). This later increase in the activated clotting time paralleled a rise in the plasma concentration of the thrombin aptamer during total CPB, as determined by high-performance liquid chromatography.(ABSTRACT TRUNCATED AT 250 WORDS)
Nucleosides, Nucleotides & Nucleic Acids | 1995
Steven H. Krawczyk; Norbert Bischofberger; Linda C. Griffin; Veronica S. Law; Regan G. Shea; S. Swaminathan
Abstract The 15-mer oligodeoxynucleotide GGTTGGTGTGGTTGG is a potent inhibitor of thrombin and it forms a stable, highly compact structure in solution. Deletions and substitutions by abasic residues, 2′-deoxyinosine, 7-deaza-2′-deoxyguanosine and 8-methyl-2′-deoxyguanosine show that the structural features of the oligodeoxynucleotide are important for its biological activity.
Archive | 1992
John J. Toole; Linda C. Griffin; Louis C. Bock; John Latham; Daryl Dean Muenchau; Steven H. Krawczyk
Archive | 1995
Linda C. Griffin; Glenn Albrecht; John Latham; Lawrence L. K. Leung; Eric Vermaas; John J. Toole
Archive | 1994
John J. Toole; John Latham; Louis C. Bock; Linda C. Griffin
Archive | 1994
John J. Toole; Linda C. Griffin; Louis C. Bock; John Latham
Antimicrobial Agents and Chemotherapy | 1998
Kenneth C. Cundy; Cathy Sueoka; Geoffrey Lynch; Linda C. Griffin; William A. Lee; Jeng-Pyng Shaw
Archive | 1992
John J. Toole; Linda C. Griffin; Louis C. Bock; John Latham; Steven H. Krawczyk
Journal of Medicinal Chemistry | 1998
Gong-Xin He; Steven H. Krawczyk; S. Swaminathan; Regan G. Shea; Joseph P. Dougherty; Terry Terhorst; Veronica S. Law; Linda C. Griffin; Steven Coutre; Norbert Bischofberger
Journal of Medicinal Chemistry | 1996
Choung U. Kim; Lawrence R. McGee; Steven H. Krawczyk; Erik Harwood; Yoko Harada; S. Swaminathan; Norbert Bischofberger; Ming S. Chen; Julie M. Cherrington; Shelly F. Xiong; Linda C. Griffin; Kenneth C. Cundy; Angela Lee; Betty Yu; Sergli Gulnik; John W. Erickson